Ironwood Pharmaceuticals (IRWD) Competitors $1.43 -0.12 (-7.74%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.07 (+4.90%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. ABBV, ZBIO, GERN, MYGN, VSTM, LXRX, RIGL, EBS, XOMA, and VNDAShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include AbbVie (ABBV), Zenas BioPharma (ZBIO), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "medical" sector. Ironwood Pharmaceuticals vs. Its Competitors AbbVie Zenas BioPharma Geron Myriad Genetics Verastem Lexicon Pharmaceuticals Rigel Pharmaceuticals Emergent Biosolutions XOMA Royalty Vanda Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Do analysts rate IRWD or ABBV? Ironwood Pharmaceuticals presently has a consensus target price of $4.94, suggesting a potential upside of 245.45%. AbbVie has a consensus target price of $234.05, suggesting a potential upside of 1.91%. Given Ironwood Pharmaceuticals' higher probable upside, research analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ironwood Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25AbbVie 0 Sell rating(s) 9 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.74 Does the media prefer IRWD or ABBV? In the previous week, AbbVie had 105 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 106 mentions for AbbVie and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 1.27 beat AbbVie's score of 1.21 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 73 Very Positive mention(s) 7 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, IRWD or ABBV? AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIronwood Pharmaceuticals$351.41M0.66$880K-$0.05-28.60AbbVie$56.33B7.20$4.28B$2.10109.36 Which has more volatility and risk, IRWD or ABBV? Ironwood Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Is IRWD or ABBV more profitable? AbbVie has a net margin of 6.45% compared to Ironwood Pharmaceuticals' net margin of -2.25%. AbbVie's return on equity of 699.66% beat Ironwood Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ironwood Pharmaceuticals-2.25% -2.46% 2.19% AbbVie 6.45%699.66%13.64% Do institutionals & insiders hold more shares of IRWD or ABBV? 70.2% of AbbVie shares are owned by institutional investors. 12.7% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAbbVie beats Ironwood Pharmaceuticals on 14 of the 17 factors compared between the two stocks. Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$251.77M$2.64B$6.11B$10.51BDividend YieldN/A57.79%5.73%4.81%P/E Ratio-28.5922.9984.5227.09Price / Sales0.66761.85609.45131.82Price / Cash31.34168.7137.1661.22Price / Book-0.765.3212.246.52Net Income$880K$33.06M$3.32B$276.75M7 Day Performance-9.78%-0.81%0.76%0.92%1 Month Performance11.72%9.20%8.03%4.20%1 Year Performance-67.79%-3.82%71.13%37.86% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.4834 of 5 stars$1.43-7.7%$4.94+245.5%-65.6%$251.77M$351.41M-28.59220Positive NewsABBVAbbVie4.6885 of 5 stars$230.28-1.6%$229.14-0.5%+19.1%$413.22B$56.33B109.6655,000Trending NewsAnalyst DowngradeOptions VolumeAnalyst RevisionZBIOZenas BioPharma2.1871 of 5 stars$23.03+5.8%$36.67+59.2%N/A$916.31M$15M-6.49N/AInsider TradeGERNGeron2.785 of 5 stars$1.28-5.2%$3.79+195.8%-70.5%$861.32M$76.99M-9.8570News CoverageMYGNMyriad Genetics3.6548 of 5 stars$7.99-0.9%$12.45+55.9%-66.2%$749.94M$837.60M-1.872,700Analyst ForecastVSTMVerastem2.9273 of 5 stars$8.61-1.0%$13.29+54.3%+185.6%$535.44M$10K-2.6350News CoverageAnalyst ForecastLXRXLexicon Pharmaceuticals2.3717 of 5 stars$1.55+9.9%$3.23+108.1%-23.0%$512.39M$31.08M-4.70140Gap DownRIGLRigel Pharmaceuticals3.5157 of 5 stars$28.90+1.3%$38.20+32.2%+79.8%$511.93M$179.28M5.34160EBSEmergent Biosolutions4.2322 of 5 stars$9.16+0.1%$13.50+47.4%+2.2%$488.16M$1.04B3.742,420Insider TradeXOMAXOMA Royalty4.2704 of 5 stars$36.61-7.8%$69.50+89.8%+23.8%$480.12M$28.49M-23.6210News CoverageVNDAVanda Pharmaceuticals4.3472 of 5 stars$5.40-0.6%$16.50+205.6%+7.6%$320.85M$198.77M-4.78290 Related Companies and Tools Related Companies AbbVie Alternatives Zenas BioPharma Alternatives Geron Alternatives Myriad Genetics Alternatives Verastem Alternatives Lexicon Pharmaceuticals Alternatives Rigel Pharmaceuticals Alternatives Emergent Biosolutions Alternatives XOMA Royalty Alternatives Vanda Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
